BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

259 related articles for article (PubMed ID: 26524186)

  • 21. Dysregulation of lymphocyte interleukin-12 receptor expression in Sézary syndrome.
    Zaki MH; Shane RB; Geng Y; Showe LC; Everetts SE; Presky DH; Wysocka M; Moore JS; Rook AH
    J Invest Dermatol; 2001 Jul; 117(1):119-27. PubMed ID: 11442758
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Increased programmed death-1 expression on CD4+ T cells in cutaneous T-cell lymphoma: implications for immune suppression.
    Samimi S; Benoit B; Evans K; Wherry EJ; Showe L; Wysocka M; Rook AH
    Arch Dermatol; 2010 Dec; 146(12):1382-8. PubMed ID: 20713771
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The Sézary syndrome: hematologic criteria.
    Vonderheid EC; Bernengo MG
    Hematol Oncol Clin North Am; 2003 Dec; 17(6):1367-89, viii. PubMed ID: 14710890
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A comparison of morphologic features, flow cytometry, TCR-Vbeta analysis, and TCR-PCR in qualitative and quantitative assessment of peripheral blood involvement by Sézary syndrome.
    Morice WG; Katzmann JA; Pittelkow MR; el-Azhary RA; Gibson LE; Hanson CA
    Am J Clin Pathol; 2006 Mar; 125(3):364-74. PubMed ID: 16613339
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Skewed expression of activation, differentiation and homing-related antigens in circulating cells from patients with cutaneous T cell lymphoma associated with CD7- T helper lymphocytes expansion.
    Scala E; Russo G; Cadoni S; Narducci MG; Girardelli CR; De Pità O; Puddu P
    J Invest Dermatol; 1999 Oct; 113(4):622-7. PubMed ID: 10504451
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The usefulness of CD26 in flow cytometric analysis of peripheral blood in Sézary syndrome.
    Kelemen K; Guitart J; Kuzel TM; Goolsby CL; Peterson LC
    Am J Clin Pathol; 2008 Jan; 129(1):146-56. PubMed ID: 18089499
    [TBL] [Abstract][Full Text] [Related]  

  • 27. CD158k/KIR3DL2 is a new phenotypic marker of Sezary cells: relevance for the diagnosis and follow-up of Sezary syndrome.
    Poszepczynska-Guigné E; Schiavon V; D'Incan M; Echchakir H; Musette P; Ortonne N; Boumsell L; Moretta A; Bensussan A; Bagot M
    J Invest Dermatol; 2004 Mar; 122(3):820-3. PubMed ID: 15086570
    [TBL] [Abstract][Full Text] [Related]  

  • 28. SC5 mAb represents a unique tool for the detection of extracellular vimentin as a specific marker of Sezary cells.
    Huet D; Bagot M; Loyaux D; Capdevielle J; Conraux L; Ferrara P; Bensussan A; Marie-Cardine A
    J Immunol; 2006 Jan; 176(1):652-9. PubMed ID: 16365461
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Heterogeneity of circulating CD4+ memory T-cell subsets in erythrodermic patients: CD27 analysis can help to distinguish cutaneous T-cell lymphomas from inflammatory erythroderma.
    Fierro MT; Novelli M; Quaglino P; Comessatti A; Fava P; Ortoncelli M; Ponti R; Bernengo MG
    Dermatology; 2008; 216(3):213-21. PubMed ID: 18182812
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Peripheral blood Sézary cells and the diagnosis of Sézary syndrome].
    Tessier-Marteau A; Le Corre Y; Gérard J; Avenel-Audran M; Geneviève F; Verret JL; Zandecki M
    Ann Biol Clin (Paris); 2008; 66(4):447-53. PubMed ID: 18725348
    [TBL] [Abstract][Full Text] [Related]  

  • 31. FOXP3+CD25- tumor cells with regulatory function in Sézary syndrome.
    Heid JB; Schmidt A; Oberle N; Goerdt S; Krammer PH; Suri-Payer E; Klemke CD
    J Invest Dermatol; 2009 Dec; 129(12):2875-85. PubMed ID: 19626037
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A restricted clonal T-cell receptor αβ repertoire in Sézary syndrome is indicative of superantigenic stimulation.
    van der Fits L; Sandberg Y; Darzentas N; Zoutman WH; Tielemans D; Wolvers-Tettero IL; Vermeer MH; Langerak AW
    Br J Dermatol; 2011 Jul; 165(1):78-84. PubMed ID: 21410672
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Significance of circulating T-cell clones in Sezary syndrome.
    Ortonne N; Huet D; Gaudez C; Marie-Cardine A; Schiavon V; Bagot M; Musette P; Bensussan A
    Blood; 2006 May; 107(10):4030-8. PubMed ID: 16418328
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Evaluation of Immunophenotypic and Molecular Biomarkers for Sézary Syndrome Using Standard Operating Procedures: A Multicenter Study of 59 Patients.
    Boonk SE; Zoutman WH; Marie-Cardine A; van der Fits L; Out-Luiting JJ; Mitchell TJ; Tosi I; Morris SL; Moriarty B; Booken N; Felcht M; Quaglino P; Ponti R; Barberio E; Ram-Wolff C; Jäntti K; Ranki A; Bernengo MG; Klemke CD; Bensussan A; Michel L; Whittaker S; Bagot M; Tensen CP; Willemze R; Vermeer MH
    J Invest Dermatol; 2016 Jul; 136(7):1364-1372. PubMed ID: 26930587
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Quantitative flow cytometric identification of aberrant T cell clusters in erythrodermic cutaneous T cell lymphoma. Implications for staging and prognosis.
    Horna P; Deaver DM; Qin D; Moscinski LC; Sotomayor EM; Glass LF; Sokol L
    J Clin Pathol; 2014 May; 67(5):431-6. PubMed ID: 24319102
    [TBL] [Abstract][Full Text] [Related]  

  • 36. CD4
    Vonderheid EC; Hou JS
    Leuk Lymphoma; 2018 Feb; 59(2):330-339. PubMed ID: 28595473
    [TBL] [Abstract][Full Text] [Related]  

  • 37. IL-21 enhances antitumor responses without stimulating proliferation of malignant T cells of patients with Sézary syndrome.
    Yoon JS; Newton SM; Wysocka M; Troxel AB; Hess SD; Richardson SK; Lin JH; Benoit BM; Kasprzycka M; Wasik MA; Rook AH
    J Invest Dermatol; 2008 Feb; 128(2):473-80. PubMed ID: 17713571
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Paucity of FOXP3+ cells in skin and peripheral blood distinguishes Sézary syndrome from other cutaneous T-cell lymphomas.
    Klemke CD; Fritzsching B; Franz B; Kleinmann EV; Oberle N; Poenitz N; Sykora J; Banham AH; Roncador G; Kuhn A; Goerdt S; Krammer PH; Suri-Payer E
    Leukemia; 2006 Jun; 20(6):1123-9. PubMed ID: 16557241
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A case of bullous Sézary syndrome.
    Ono A; Isomura I; Isogai Z; Shintani Y; Suzuki A; Morita A
    J Dermatol; 2004 Dec; 31(12):1027-31. PubMed ID: 15801270
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Evidence for restricted Vbeta usage in the leukemic phase of cutaneous T cell lymphoma.
    Vonderheid EC; Boselli CM; Conroy M; Casaus L; Espinoza LC; Venkataramani P; Bigler RD; Hou JS
    J Invest Dermatol; 2005 Mar; 124(3):651-61. PubMed ID: 15737208
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.